Abbott Laboratories (ABT) · Other

DICK'S Sporting Goods Inc (DKS) · Earnings Release

Q1 2026 earnings release is scheduled for 2026-05-27. Medium importance estimated as earnings releases for high-growth companies typically result in ≥5% price movement. Analysts forecast EPS of approximately $2.93 forecasted.

5/27/2026, 12:00:00 AM

Novo Nordisk A/S (NVO) · Earnings Release

High importance estimated as earnings releases for major pharma often result in >10% price movement. Q1 2026 earnings release scheduled. Analysts forecast EPS of $0.87 and revenue of $11.35 billion forecasted.

5/6/2026, 12:00:00 AM

Eli Lilly and Co (LLY) · Earnings Release

Eli Lilly reported Q1 2026 revenue of $19.8 billion (+56% YoY) and non-GAAP EPS of $8.55, beating estimates. The company raised its full-year 2026 revenue guidance to $82-$85 billion, driven by strong sales of Mounjaro and Zepbound. This significant growth and guidance raise is estimated to result in a >10% price impact.

4/30/2026, 12:00:00 AM

Eli Lilly and Co (LLY) · Other

The U.S. FDA proposed removing tirzepatide, the active ingredient in Mounjaro and Zepbound, from the bulk drug substances list on 2026-04-30, restricting compounded versions. This regulatory protection of market share is estimated to result in a >10% price impact.

4/30/2026, 12:00:00 AM

Merck and Co Inc (MRK) · Earnings Release

Reported Q1 2026 financial results, posting a GAAP Loss per Share of $1.72, which included a $3.62 per share charge from the acquisition of Cidara Therapeutics. Revenue grew 5% to $16.3 billion. The company raised its full-year 2026 guidance; high importance due to guidance raise and acquisition impact, market reaction expected.

4/30/2026, 12:00:00 AM

Novo Nordisk A/S (NVO) · Other

High importance estimated as this regulatory change protects core revenue from competition, likely impacting price by >10%. The U.S. FDA proposed to exclude the active ingredients in key Novo Nordisk GLP-1 drugs from the bulk compounding list.

4/30/2026, 12:00:00 AM